A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia

Atherosclerosis

Volumn 162, Issue 2, 2002, Pages 373-379

  Saito, Yasushi ^a   Yamada, Nobuhiro ^b   Teramoto, Tamio ^c   Itakura, Hiroshige ^d   Hata, Yoshiya ^e   Nakaya, Noriaki ^f   Mabuchi, Hiroshi ^g   Tushima, Motoo ^h   Sasaki, Jun ⁱ   Ogawa, Nobuya ^j   Goto, Yuichiro ^k  

^a CHIBA UNIVERSITY   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c TEIKYO UNIVERSITY   (Japan)

^d The National Health and Nutrition Research Laboratory   (Japan)

^e KYORIN UNIVERSITY   (Japan)

^f Fussa National Health Insurance Hospital   (Japan)

^g KANAZAWA UNIVERSITY   (Japan)

^h NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

ⁱ FUKUOKA UNIVERSITY   (Japan)

^j EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k TOKAI UNIVERSITY   (Japan)

more..

Author keywords

Controlled study; Double blind; HMG CoA reductase inhibitor; Hypercholesterolemia; Pitavastatin; Pravastatin; Randomized

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PRAVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEPATITIS C; HUMAN; HYPERCHOLESTEROLEMIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TRIACYLGLYCEROL BLOOD LEVEL; VERTIGO;

ADULT; AGED; CHOLESTEROL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PRAVASTATIN; QUINOLINES; SAFETY;

EID: 0036234655     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(01)00712-2     Document Type: Article

References (25)

1. Cholesterol and mortality: 30 years of follow-up from the Framingham study
2. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screeners of the Multiple Risk Factor Intervention Trial (MRFIT)
3. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators
4. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
5. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S)
6. Cholesterol reduction yields clinical benefit: Impact of statin trial
7. A review of clinical trials comparing HMG-CoA reductase inhibitors
8. Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia
9. Comparison of the effects on quality of life and the efficacy and tolerability of lovastatin versus pravastatin
10. Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia
11. A randomized multicenter trial comparing the efficacy of simvastatin and fluvastatin
12. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia
13. Treating hypercholesterolemia with HMG CoA reductase inhibitors: A direct comparison of simvastatin and pravastatin
14. Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults. (Adult Treatment Panel II)
15. Recommendations of the European Atherosclerosis Society prepared by the International Task Force for Prevention of Coronary Heart Disease
16. Prevention of coronary heart diseases and lipid-lowering therapy in Japan
17. Pharmacological profile of a novel synthetic inhibitor of 3 hydroxy-3-metylglutaryl-coenzyme A reductase
18. Hypolipidemic effect of NK-104, a potent HGM-CoA reductase inhibitor, in guinea pigs
19. NK-104, a newly developed HMG-CoA reductase inhibitor, suppresses neointimal thickening by inhibiting smooth muscle cell growth and fibronectin production in balloon-injured rabbit carotid artery
20. Comparison of 1-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia
21. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia
22. A multicenter, double-blind, 1-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia
23. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES Study)
24. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase